Silence Therapeutics - Additional listing and Total Voting Rights

Silence Therapeutics

25/01/2021 12:41

RNS Number : 7920M

Silence Therapeutics PLC

25 January 2021

 

 

Additional listing and Total Voting Rights

January 25, 2021

 

LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that it has issued and allotted 3,000 new ordinary shares of 5p each ("New Ordinary Shares") following the exercise of share options under the Employee Share Option Scheme.

 

Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on January 29, 2021. The New Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.

 

The total number of ordinary shares of 5p each in issue, following admission of the New Ordinary Shares, will be 83,309,259. The Company holds no shares in Treasury.  This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules. 

 

 

Enquiries:

 

Silence Therapeutics plc
Gem Hopkins, Head of IR & Corporate Communications
ir@silence-therapeutics.com
Tel:  +1 (646) 637-3208
Investec Bank plc (Nominated Adviser and Broker)
Daniel Adams/Gary Clarence
Tel: +44 (0) 20 7597 5970
European IR
Consilium Strategic Communications
Mary-Jane Elliott/Chris Welsh/Angela Gray
silencetherapeutics@consilium-comms.com
Tel: +44 (0) 20 3709 5700


 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary technology can be used to engineer short interfering ribonucleic acids (siRNAs) that bind specifically to and silence, through the RNAi pathway, almost any gene in the human genome to which siRNA can be delivered. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of Lipoprotein(a) and SLN124 to address beta-thalassemia and myelodysplastic syndrome. Silence is also developing SLN500, a C3 targeting program, in partnership with Mallinckrodt Pharmaceuticals to reduce the expression of the C3 protein for the treatment of complement pathway-mediated diseases.  Silence maintains ongoing research and collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
ALSDKPBNBBKDCDB